Skip to main
  1. Stocks
  2. First Tracks Biotherapeutics Inc
  3. Forecast
TRAX

TRAX Stock Forecast & Price Target

TRAX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 64%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

First Tracks is supported by a clinically de-risked lead asset in ANB033, which delivered statistically significant and clinically meaningful benefit in Phase Ib celiac disease and is advancing with Cohort 2 topline data on track for 1Q27 and a late-stage celiac program expected in 2027. The bull case is strengthened by multiple near-term catalysts across the pipeline—ongoing EoE enrollment with data in 3Q27, a planned vitiligo Phase II start in 1H27, and additional indication disclosure in 1H27—while external IL-15/CD122 and BDCA2 readthroughs have validated the company’s mechanism and broadened its commercial potential. Financially, the outlook is further supported by sum-of-the-parts models that ascribe meaningful NPV to ANB033 across celiac, EoE, and vitiligo, plus anticipated YE27 net cash, with recent capital raise dilution already reflected in valuations.

Bears say

First Tracks is exposed to substantial clinical and mechanism risk, as ANB033 and ANB101 could fail in celiac disease, EoE, vitiligo, or beyond Phase 1, while competitor setbacks could still cast doubt on CD122 and BDCA2 validation. The company also faces commercialization risk because rosnilimab may not find a partner, and the excerpts highlight a crowded autoimmune landscape where differentiated efficacy and safety will be hard to prove. As a clinical-stage biotech with no stated cash-generating base, it could burn more cash than expected and be forced into financing that dilutes shareholders and pressures returns.

TRAX has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 64% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

TRAX Analyst Forecast & Price Prediction

Get the latest TRAX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TRAX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About First Tracks Biotherapeutics Inc (TRAX) Forecast

Analysts have given TRAX a Buy based on their latest research and market trends.

According to 11 analysts, TRAX has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

First Tracks Biotherapeutics Inc (TRAX)


TRAX Analyst Forecast & Price Prediction

Get the latest TRAX stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in TRAX

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TRAX stock data and trends